Gusacitinib-d4

Gusacitinib-d4 (ASN-002-d4) is the deuterium labeled Gusacitinib (HY-103018) . Gusacitinib (ASN-002) is an orally active dual SYK/JAK kinase inhibitor with IC50 values of 5, 46, 4, 11 and 8 nM for SYK, JAK1, JAK2, JAK3 and TYK2, respectively. Gusacitinib rapidly and significantly suppressed key inflammatory pathways implicated in atopic dermatitis pathogenesis. Gusacitinib can be used in the research of chronic hand eczema and cancers such as basal cell carcinoma[1][2].

Product Specifications

Product Name Alternative

ASN-002-d4

UNSPSC

12352005

Target

Isotope-Labeled Compounds; JAK; Syk

Related Pathways

Epigenetics; JAK/STAT Signaling; Others; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Field of Research

Cancer; Inflammation/Immunology

Smiles

N#CCC1CCN(C2=NC(NC3=C([2H])C([2H])=C(N4CCC(O)CC4)C([2H])=C3[2H])=C5C(C=NNC5=O)=N2)CC1

Molecular Formula

C24H24D4N8O2

Molecular Weight

464.56

References & Citations

[1]Xie Z, et al. Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases. J Med Chem. 2021 Feb 11;64 (3) :1283-1345. |[2]Garcia-Melendo C, et al. Janus Kinase Inhibitors in Dermatology: Part 1 - General Considerations and Applications in Vitiligo and Alopecia Areata. Actas Dermo-Sifiliográficas, 2021, 112 (6) : 503-515.